In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on DBV Technologies SA – American, with a price target of $19.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sam Slutsky’s rating is based on several promising developments at DBV Technologies. The company has achieved significant progress by securing written alignment with the FDA on approval paths for its Viaskin Peanut therapy, targeting both 1–3-year-olds and 4–7-year-olds. The upcoming Phase 3 VITESSE trial, expected to deliver results by Q4 2025, is a critical step toward a Biologics License Application (BLA) submission planned for the first half of 2026. This trial will assess the efficacy of Viaskin Peanut over a 12-month period, focusing on patients’ tolerance to peanut protein compared to a placebo.
Additionally, DBV Technologies has bolstered its financial position with a structured financing deal of up to $306.9 million, which is anticipated to support the company through the commercialization phase in the US. This financial strategy, combined with the potential success of the VITESSE trial, positions Viaskin Peanut closer to US approval. With a current cash balance of $103.2 million and a clear path to potential FDA approval, DBV Technologies is well-positioned for growth, justifying the Buy rating.